Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
- 27 April 2020
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 19 (1) , 55-65
Abstract
Background & Objective: The pharmacokinetics and acute toxicity of a histone deacetylase inhibitor, Scriptaid, was unknown in the mouse. The aim of this study was to determine the pharmacokinetics, acute toxicity, and tissue distribution of Scriptaid, a new histone deacetylase inhibitor, in mice, and its neuroprotective efficacy in a mouse intracranial hemorrhage (ICH) model. Methods: The pharmacokinetics, acute toxicity, and tissue distribution were determined in C57BL/6 male and female mice after the intraperitoneal administration of a single dose. Behavioral tests, as well as investigations of brain atrophy and white matter injury, were used to evaluate the neuroprotective effect of Scriptaid after ICH. Western blotting was used to investigate if Scriptaid could offer antiinflammatory benefits after ICH. Results: No significant differences were observed in body weight or brain histopathology between the group that received Scriptaid at 50 mg/kg and the group that received dimethyl sulfoxide (control). The pharmacokinetics of Scriptaid in mice was nonlinear, and it was cleared rapidly at low doses and slowly at higher doses. Consistent with the pharmacokinetic data, Scriptaid was found to distribute in several tissues, including the spleen and kidneys. In the ICH model, we found that Scriptaid could reduce neurological deficits, brain atrophy, and white matter injury in a dose-dependent manner. Western blotting results demonstrated that Scriptaid could decrease the expression of pro-inflammatory cytokines IL1β and TNFα, as well as iNOS, after ICH. Conclusion: These findings indicate that Scriptaid is safe and can alleviate brain injury after ICH, thereby providing a foundation for the pharmacological action of Scriptaid in the treatment of brain injury after ICH.Keywords
Funding Information
- National Ministry of Science and Technology (2014CB541604, 2016YFC1301702, 2016YFSF110141)
- National Natural Science Foundation of China (81500987, 817712374, 81801155, 81870917)
- Science and Technology Commission of Shanghai Municipality (15140902300)
- Shanghai Municipal Planning Commission of Science and Research Fund (2017BR022)
- Fudan University (2016QD082)
This publication has 32 references indexed in Scilit:
- Histone Deacetylase 7 Promotes Toll-like Receptor 4-dependent Proinflammatory Gene Expression in MacrophagesJournal of Biological Chemistry, 2013
- Synthesis and pharmacokinetics of strontium fructose 1,6-diphosphate (Sr-FDP) as a potential anti-osteoporosis agent in intact and ovariectomized ratsJournal of Inorganic Biochemistry, 2011
- Preclinical and clinical research on inflammation after intracerebral hemorrhageProgress in Neurobiology, 2010
- HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activityJournal of Cellular and Molecular Medicine, 2009
- Histone Deacetylase Inhibitors: Overview and PerspectivesMolecular Cancer Research, 2007
- Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activationNeurobiology of Disease, 2007
- Inflammation after Intracerebral HemorrhageJournal of Cerebral Blood Flow & Metabolism, 2007
- HDAC inhibitors as anti‐inflammatory agentsBritish Journal of Pharmacology, 2007
- Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?Drug Discovery Today, 2005
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001